| Dr Annette Lusko, DO | |
|
1855 W Baseline Rd Ste 101, Mesa, AZ 85202-9098 | |
| (480) 507-3188 | |
| Not Available |
| Full Name | Dr Annette Lusko |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 1855 W Baseline Rd Ste 101, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487918181 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11016763A (Indiana) | Secondary |
| 207Q00000X | Family Medicine | 006726 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Bridges Inc | 2062699721 | 73 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
| Entity Name | Heritage Technologies Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093764938 PECOS PAC ID: 5193628485 Enrollment ID: O20040526000631 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
| Entity Name | Tri-city Express Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962580118 PECOS PAC ID: 2264436377 Enrollment ID: O20060901000335 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
| Entity Name | Community Bridges Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558095315 PECOS PAC ID: 2062699721 Enrollment ID: O20110606000388 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
| Entity Name | Teri's Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215422126 PECOS PAC ID: 2163857392 Enrollment ID: O20200116002404 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Annette Lusko, DO 1855 W Baseline Rd Ste 101, Mesa, AZ 85202-9098 Ph: (480) 390-1085 | Dr Annette Lusko, DO 1855 W Baseline Rd Ste 101, Mesa, AZ 85202-9098 Ph: (480) 507-3188 |
News Archive
Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
The University of Texas MD Anderson Cancer Center today announced an agreement with Hospital Israelita Albert Einstein (HIAE) in São Paulo, Brazil, creating an alliance to develop a comprehensive, multidisciplinary oncology program at the hospital.
A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.
› Verified 2 days ago
Dr. Jose Rapanan Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10032 E Southern Ave, Mesa, AZ 85209 Phone: 480-351-2850 | |
Jennifer Christine Fendler, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 924 N Country Club Dr, Mesa, AZ 85201 Phone: 480-601-3528 | |
George Ting, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1111 N Stapley Dr, Mesa, AZ 85203 Phone: 480-464-8500 | |
Dr. Thomas P Porter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1950 S Country Club Dr, Mesa, AZ 85210 Phone: 480-969-1446 Fax: 480-969-9105 | |
Dana S Farris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10238 E Hampton Ave Ste 506, Mesa, AZ 85209 Phone: 480-834-7546 Fax: 480-833-8313 | |
Nancy Mucha, CNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2843 N 89th St, Mesa, AZ 85207 Phone: 480-396-3482 | |
Ryan Elisabeth Romo, Family Medicine Medicare: Medicare Enrolled Practice Location: 1705 W Main St, Mesa, AZ 85201 Phone: 877-809-5092 |